ORR per IRC assessment and lymph node response rate for the total CLL/SLL study population for duvelisib vs ofatumumab monotherapy. Lymph node response was defined as ≥50% decrease in the sum of the products of target lymph nodes. Both the ORR (P < .0001) and the lymph node response rate (P < .0001) were significantly higher in duvelisib-treated patients.